Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Net CRISPR Activation Plasmid (h): sc-405945-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Net CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Net CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Net CRISPR Activation Plasmid (h) and Net CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the ELK3 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Net Antibody (11G9): sc-134401
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Net CRISPR Activation Plasmid (h) | sc-405945-ACT | 20 µg | $397.00 |
ELK3 (Net) is an ETS-domain transcription factor that functions predominantly as a transcriptional repressor and context-dependent activator downstream of RAS–RAF–MEK–ERK signaling. By forming ternary complexes with serum response factor at serum response elements, Net integrates mitogen and stress cues to regulate immediate-early gene programs, cytoskeletal remodeling, and cell-state transitions. Net activity influences processes such as endothelial biology, migration, and invasion through regulation of target genes linked to MAPK-driven transcriptional outputs. Dysregulated ELK3 expression or signaling has been associated with oncogenic programs, angiogenesis-related phenotypes, and metastatic potential, making it a relevant node for mechanistic studies of tumor progression and vascular remodeling.
Net CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous ELK3 expression without altering the underlying DNA sequence.
Net CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the ELK3 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the ELK3 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Net expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native ELK3 locus and enabling the study of Net-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Net pathway restoration in tumor cells with silenced or reduced ELK3 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.